Your institution may have access to this item. Find your institution then sign in to continue.
Title
Alipogene tiparvovec approved for lipoprotein lipase deficiency.
Abstract
The article reports that in 2012 the European Medicines Agency's Committee for Medicinal Products for Human Use made to approve the drug alipogene tiparvovec for the treatment of lipoprotein lipase deficiency in patients with pancreatitis attacks.